Scalzo Richard William — SEC insider filings

SEC reporting owner CIK 1789545. 38 insider filings on record with FilingPulse; latest filed 2026-09-18.

Transaction summary — filings shown

Covers all 38 filings on record, filed 2020-09-18 to 2026-09-18. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Dyne Therapeutics, Inc. (DYN)SVP, Head of Finance & Admin.35—40 legs · 339,244 sh · $8,710,78243
CRESCENT BIOPHARMA, INC. (CBIO)Chief Financial Officer3—2 legs · 1,680 sh · $30,1723

Insider filings — Scalzo Richard William

FiledFormIssuerReported transactionsSource
2026-09-184CRESCENT BIOPHARMA, INC. (CBIO)Sale (S): 568 @ $17.90EDGAR
2026-06-234CRESCENT BIOPHARMA, INC. (CBIO)Sale (S): 1,112 @ $17.99EDGAR
2025-12-174CRESCENT BIOPHARMA, INC. (CBIO)Grant/award (A): 14,422 · Grant/award (A): 5,000 · Grant/award (A): 57,688 (derivative) @ $0EDGAR
2025-03-134Dyne Therapeutics, Inc. (DYN)Sale (S): 1,343 @ $11.38EDGAR
2025-03-074Dyne Therapeutics, Inc. (DYN)Sale (S): 917 @ $11.83EDGAR
2025-02-184Dyne Therapeutics, Inc. (DYN)Sale (S): 2,488 @ $13.95EDGAR
2024-12-114Dyne Therapeutics, Inc. (DYN)Sale (S): 1,455 @ $28.12EDGAR
2024-12-064Dyne Therapeutics, Inc. (DYN)Grant/award (A): 32,700 @ $0 · Grant/award (A): 52,300 (derivative) @ $0EDGAR
2024-11-184Dyne Therapeutics, Inc. (DYN)Sale (S): 2,735 @ $28.20EDGAR
2024-09-194Dyne Therapeutics, Inc. (DYN)Sale (S): 1,390 @ $34.55EDGAR
2024-09-114Dyne Therapeutics, Inc. (DYN)Sale (S): 1,468 @ $31.89EDGAR
2024-09-104Dyne Therapeutics, Inc. (DYN)Option exercise (M): 6,502 @ $5.54 · Option exercise (M): 3,353 @ $5.54 · Option exercise (M): 34,833 @ $19 · Option exercise (M): 16,696 @ $13.12 · Option exercise (M): 29,792 @ $8.58 · Option exercise (M): 18,750 @ $10.72 · +10 moreEDGAR
2024-08-204Dyne Therapeutics, Inc. (DYN)Sale (S): 2,442 @ $45.01 · Sale (S): 310 @ $46EDGAR
2024-06-114Dyne Therapeutics, Inc. (DYN)Sale (S): 1,590 @ $30.23 · Sale (S): 1,331 @ $31.34EDGAR
2024-05-174Dyne Therapeutics, Inc. (DYN)Sale (S): 2,126 @ $28.20 · Sale (S): 462 @ $28.59EDGAR
2024-03-124Dyne Therapeutics, Inc. (DYN)Option exercise (M): 68,919 @ $5.54 · Option exercise (M): 17,333 @ $5.54 · Sale (S): 30,755 @ $25.31 · Sale (S): 55,208 @ $26.72 · Sale (S): 289 @ $27.33 · Sale (S): 1,082 @ $25.70 · +3 moreEDGAR
2024-03-114Dyne Therapeutics, Inc. (DYN)Sale (S): 2,273 @ $25.85EDGAR
2024-03-014Dyne Therapeutics, Inc. (DYN)Option exercise (M): 3,429 @ $1.03 · Sale (S): 3,429 @ $27.50 · Option exercise (M): 9,311 @ $1.03 · Sale (S): 8,747 @ $28.22 · Sale (S): 564 @ $28.65 · Option exercise (M): 3,429 (derivative) @ $0 · +1 moreEDGAR
2024-01-264Dyne Therapeutics, Inc. (DYN)Option exercise (M): 13,000 @ $1.03 · Sale (S): 13,000 @ $24.34 · Option exercise (M): 13,000 (derivative) @ $0EDGAR
2024-01-044Dyne Therapeutics, Inc. (DYN)Option exercise (M): 13,000 @ $1.03 · Sale (S): 13,000 @ $18.81 · Option exercise (M): 13,000 (derivative) @ $0EDGAR
2023-12-144Dyne Therapeutics, Inc. (DYN)Sale (S): 2,376 @ $12.02EDGAR
2023-12-124Dyne Therapeutics, Inc. (DYN)Sale (S): 1,380 @ $10.72EDGAR
2023-12-064Dyne Therapeutics, Inc. (DYN)Sale (S): 681 @ $12.01 · Sale (S): 1,872 @ $12.01EDGAR
2023-11-164Dyne Therapeutics, Inc. (DYN)Grant/award (A): 89,742 @ $0 · Grant/award (A): 34,946 (derivative) @ $0EDGAR
2023-09-204Dyne Therapeutics, Inc. (DYN)Sale (S): 1,290 @ $9.41EDGAR
2023-09-134Dyne Therapeutics, Inc. (DYN)Sale (S): 1,397 @ $10.41EDGAR
2023-06-154Dyne Therapeutics, Inc. (DYN)Sale (S): 1,390 @ $12.43 · Option exercise (M): 40,000 @ $1.03 · Sale (S): 40,000 @ $12.89 · Sale (S): 10,000 @ $12.03 · Option exercise (M): 40,000 (derivative) @ $0EDGAR
2023-03-154Dyne Therapeutics, Inc. (DYN)Sale (S): 1,311 @ $13.33EDGAR
2022-12-134Dyne Therapeutics, Inc. (DYN)Grant/award (A): 31,000 @ $0 · Sale (S): 312 @ $10.87 · Grant/award (A): 45,000 (derivative) @ $0EDGAR
2022-09-214Dyne Therapeutics, Inc. (DYN)Disposition to issuer (D): 840 @ $13.70EDGAR
2022-09-154Dyne Therapeutics, Inc. (DYN)Disposition to issuer (D): 326 @ $14.05EDGAR
2022-07-134Dyne Therapeutics, Inc. (DYN)Grant/award (A): 55,000 (derivative) @ $0EDGAR
2022-07-064Dyne Therapeutics, Inc. (DYN)Grant/award (A): 17,333 (derivative) @ $0EDGAR
2022-06-154Dyne Therapeutics, Inc. (DYN)Disposition to issuer (D): 333 @ $4.95EDGAR
2022-03-144Dyne Therapeutics, Inc. (DYN)Sale (S): 308 @ $8.73EDGAR
2021-12-144Dyne Therapeutics, Inc. (DYN)Grant/award (A): 16,696 @ $0 · Grant/award (A): 25,044 (derivative) @ $0EDGAR
2021-09-224Dyne Therapeutics, Inc. (DYN)Sale (S): 367 @ $15.61 · Sale (S): 492 @ $16.11EDGAR
2020-09-184Dyne Therapeutics, Inc. (DYN)Grant/award (A): 11,465 @ $0 · Grant/award (A): 35,575 (derivative) @ $0EDGAR

FilingPulse's Form 4 archive currently extends back to 2020-09-16 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1789545 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs